Braveheart Bio Raises $382.5M in U.S. IPO to Battle Heart Disease
Heart disease-focused biotech Braveheart Bio has raised $382.5 million in its U.S. IPO. Investor Demand Beats Expectations The San Francisco-based ...
Kardigan Inc. (KARD)
Market is closed
Sector: Pharmaceutical Preparations
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 3,125,000 | $50,000,000.00 | 14,866,868 | 2026-06-22 | Filing | |
| $16.00 | 1,250,000 | $20,000,000.00 | 15,042,035 | 2026-06-22 | Filing | |
| $16.00 | 1,250,000 | $20,000,000.00 | 15,042,035 | 2026-06-22 | Filing |
News See All
2 ‘Strong Buy’ IPO Stocks JPMorgan Thinks Are Worth Watching
The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditio...
Hedge Fund Resource Center